Ranitidine Cancer Lawsuits Continue in Florida Courts Following Zantac Recalls

15 Zantac lawsuit plaintiffs have been transferred to South Florida court, where multidistrict litigation has been filed on behalf of individuals who have been diagnosed with cancer subsequent to taking Zantac and similar ranitidine products.

According to the transfer order, which was approved by federal judges, there are currently 126 cases pending in 21 districts nationwide. With the increasing number of Zantac recalls and Zantac-like product recalls across the nation, the Southern Florida court could potentially see a major surge in the number of Zantac lawsuit cases to follow.

The Zantac lawsuit MDL currently consists both of individual plaintiffs alleging personal injury and punitive damage class action lawsuits.

Plaintiffs in the lawsuits claim that Zantac and similar products contain a dangerous quantity of potential carcinogen, NDMA. The FDA in September confirmed the presence of NDMA in Zantac and ranitidine products.

The FDA’s announcement was followed by a number of voluntary recalls of the drug.

Plaintiff injuries include liver cancer, bladder cancer, and other types of cancer, which they attribute to NDMA in Zantac. According to the filings, plaintiffs accuse manufacturers, sellers and distributors of knowingly putting consumers at risk and actively hiding Zantac dangers from consumers.

U.S. District Judge Robin Rosenberg has been assigned to preside over the Zantac lawsuit, which is filed in the U.S. District Court for the Southern District of Florida.